Cytarabine and daunorubicin liposomal (Vyxeos)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 15:26, 10 June 2014 by Jwarner (talk | contribs)
Jump to navigation Jump to search

Mechanism of action

This drug is a liposomal formulation of Cytarabine (Cytosar) and Daunorubicin (Cerubidine) in a 5:1 molar ratio.

Preliminary data

  1. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46. Epub 2014 Mar 31. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Cytarabine_and_daunorubicin_liposomal_(Vyxeos)&oldid=4725"